Is Your Paper Ready for Nature Reviews Drug Discovery? The Invitation-Only Reality
Nature Reviews Drug Discovery does not accept unsolicited primary research. Here is what the commissioned model means and where drug discovery research papers actually belong.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Quick answer: Your primary research paper is not ready for Nature Reviews Drug Discovery because the journal is not an open primary-research target. If you're asking "is my paper ready for Nature Reviews Drug Discovery," you are only ready with an invited or editor-discussed review proposal, recognized authority, a tight topic map, and a synthesis article package.
This guide separates Nature Portfolio's official author information from Manusights editorial interpretation. Official pages explain the commissioned review model. The reader-facing value here is the readiness decision: whether you are preparing a Nature Reviews Drug Discovery proposal or whether your abstract, methods, figures, pharmacology data, references, and cover letter belong at a primary research journal instead.
Methodology note
This page was updated by a Manusights researcher using Nature Reviews Drug Discovery author information, Nature Portfolio author guidance, adjacent primary research journal instructions, JCR metric references, and Manusights internal analysis of drug discovery manuscript routing patterns. Use this guide before you submit or approach editors, then check the Nature Reviews Drug Discovery journal profile or run a free manuscript readiness scan.
Source limitation: we used public official guidance and published journal information; we did not test Nature Reviews Drug Discovery's private editorial proposal workflow or claim access to confidential editorial files.
Nature Reviews Drug Discovery readiness verdict
Submit if: an editor has invited you, or you have a concise review proposal with topic authority, author credentials, a current literature map, article-type fit, and a reason the synthesis is needed now.
Think twice if: you have primary target biology, medicinal chemistry, pharmacology, ADMET, screening, or translational data. Those papers need a primary research journal, not Nature Reviews Drug Discovery.
Official Nature Reviews Drug Discovery requirements table
Requirement | What the journal asks for | Readiness risk | Source |
|---|---|---|---|
Article type | Review and perspective-style content prepared for Nature Reviews | Immediate mismatch if the package is a primary research manuscript | Official author information |
Submission model | Invitation-led editorial process, with author guidance from the journal team | Low likelihood of success without editor interest or clear author authority | Official author information |
Manuscript package | Topic proposal, article outline, references, display items, and synthesis plan rather than experimental methods | Rejection or no response if the proposal reads like a research article abstract | Nature Reviews author guidance |
APC and publication route | Nature Portfolio review journal, not a standard open primary-research route | Planning risk if the author expects ordinary article processing and peer review mechanics | Official journal information |
Source: Nature Reviews Drug Discovery author information and Nature Reviews author guidance, accessed June 2026.
Nature Reviews Drug Discovery readiness matrix
Readiness area | Ready for Nature Reviews Drug Discovery | Borderline | High-risk decision |
|---|---|---|---|
Scope fit | Drug discovery synthesis with clear value for academic, biotech, pharma, and clinical translation readers | Good topic, but the synthesis may be too narrow or already well covered | Primary research, single-lab update, or unsynthesized literature summary |
Methods | For a review proposal: search logic, reference map, topic boundaries, figure plan, and author roles are clear | Proposal has topic promise but weak coverage plan | Experimental methods section, animal data, or compound series presented as the submission core |
Evidence | References, clinical or translational context, and display items support a field-level argument | Strong references but no opinion or organizing framework | Data package belongs to a primary research manuscript |
Package | Proposal, author qualifications, outline, figures or tables, references, and cover note explain why this review now | Author credentials are strong but the article thesis is vague | Cover letter asks to submit a primary manuscript |
Risk | Editor can see why this author team and topic belong in a commissioned review format | Editor may redirect to another Nature Reviews title or article type | Immediate mismatch because the manuscript is not a review proposal |
What Nature Reviews Drug Discovery actually is
Nature Reviews Drug Discovery is a Nature Portfolio journal launched in 2002 that covers the full spectrum of drug discovery: target biology, chemical optimization, pharmacokinetics, clinical development, and regulatory science. According to the journal's author information, the journal publishes Reviews, Perspectives, and Comments that synthesize knowledge, analyze trends, and provide opinion on drug discovery topics from leading researchers, clinicians, and industry scientists.
The editorial model is commission-driven: editors identify topics where an authoritative synthesis would serve the field, then invite researchers and industry scientists whose work has shaped understanding in that area.
The scope spans therapeutic areas from oncology and cardiovascular disease to rare diseases and infectious disease, covering both small-molecule and biologic drug discovery. The journal holds a distinctive position because it bridges academic research, pharmaceutical industry science, and clinical development in a way that few chemistry or biology journals do. Authors invited to write for Nature Reviews Drug Discovery are often active or former pharmaceutical industry scientists with direct clinical program experience, or academic researchers who have led target validation programs that have advanced to development.
Per Nature Portfolio editorial policy, the journal does not accept unsolicited primary research manuscripts. Researchers who wish to propose a review or perspective article should contact the editors directly with a brief proposal, but the bar for a proactive approach is high: the editorial team receives more proposals than it can accommodate, and priority goes to topics where the invited author team's credentials match the breadth the review requires.
The numbers that matter
Feature | Nature Reviews Drug Discovery |
|---|---|
Impact Factor (2024 JCR) | ~72.0 |
Submission model | Invitation-only |
Article types | Reviews, Perspectives, Comments |
Acceptance rate (invited) | Controlled by invitation selectivity |
Time from invitation to publication | 4 to 8 months |
Publisher | Nature Portfolio (Springer Nature) |
Who gets invited and why
Nature Reviews Drug Discovery editors track both the academic literature and the pharmaceutical pipeline closely. According to the journal's editorial model, invitation candidates fall into two main categories: academic researchers who have published foundational work in a target area or therapeutic mechanism, and pharmaceutical or biotech industry scientists who have led or closely participated in clinical programs that reached a decision point worth analyzing.
The drug discovery literature is different from basic science in one important respect: the editorial team values industry experience and clinical translational knowledge as highly as academic citation prominence. A researcher who has published 20 papers on a kinase target in journals like JACS or Nature Chemical Biology and also consulted on or led an industry target validation program is a stronger invitation candidate than a researcher with the same academic record but no translational connection.
There is no structured pre-submission inquiry form. Researchers who want to approach the journal should email the editorial office with a two-paragraph proposal covering the topic scope, the author team's qualifications, and why this synthesis is needed now rather than being a duplicate of a recent review in the area.
What to do if you want to build toward an invitation
The path to an invitation from Nature Reviews Drug Discovery runs through a combination of primary research depth and demonstrated synthesis ability in the drug discovery context.
- Publish primary target biology, pharmacology, or medicinal chemistry research in Nature Chemical Biology, Journal of Medicinal Chemistry, Cell Chemical Biology, or Nature Biotechnology in a defined therapeutic area
- Develop visible expertise in a specific target class, therapeutic modality, or clinical problem area so that editors can see where your synthesis authority lies
- Write shorter perspective or opinion pieces for Drug Discovery Today, ACS Medicinal Chemistry Letters, or Nature Chemical Biology perspectives to develop the synthesis voice
- Participate in pharmaceutical industry advisory work, clinical trial committees, or regulatory review panels that deepen the translational context
- Present at major drug discovery conferences where Nature Reviews editors are present, including the American Chemical Society medicinal chemistry symposia, SCI and RSC medicinal chemistry meetings, and AACR or AHA where target areas are represented
Submit If
Submit or approach the editors only if the package is a review proposal, not a primary research manuscript. The proposal should define the topic boundary, explain the synthesis angle, name the author team's authority, and show how the review would organize a field rather than summarize a single group's data. The cover note should be short, editorial, and specific.
Submit if the proposed article can serve readers across academia, biotechnology, pharmaceutical development, and translational medicine. A Nature Reviews Drug Discovery article needs figures, tables, references, and narrative structure that help readers make sense of a target class, therapeutic modality, development bottleneck, regulatory problem, or clinical translation path.
Think Twice If
Think twice if the manuscript has a methods section, original figures, new compound data, animal efficacy results, pharmacokinetic experiments, or a primary endpoint. Those are signs that the paper belongs at a research journal. Nature Reviews Drug Discovery may cite that work later, but it is not the right venue for publishing it.
Think twice if the proposal is really "we have worked in this area, so we can review it." The journal needs a topic that is timely, organized, and useful to the field. A review proposal without a sharp thesis, current reference map, and credible author team will read like a request for visibility rather than an editorial contribution.
How Nature Reviews Drug Discovery compares with research journals in the field
Journal | IF (2024) | Acceptance rate | Submission model | Best for |
|---|---|---|---|---|
Nature Reviews Drug Discovery | ~72.0 | N/A (invited) | Invitation-only | Commissioned synthesis of drug discovery topics |
~14.8 | ~8% | Open | Chemical biology mechanisms with therapeutic relevance | |
~33.1 | ~8% | Open | Translational biotechnology with clinical development path | |
~6.8 | ~30% | Open | Medicinal chemistry, SAR, and drug design across therapeutic areas | |
~6.9 | ~20% | Open | Chemical biology at the interface of drug discovery and target biology | |
~6.5 | ~35% | Open | Applied drug discovery and development across therapeutic areas |
Per the 2024 JCR, the IF difference between Nature Reviews Drug Discovery and primary research journals reflects the citation density of authoritative reviews rather than a quality ranking. A foundational paper in Nature Chemical Biology or Journal of Medicinal Chemistry is the career-building primary research move; an invitation to review in Nature Reviews Drug Discovery follows from a sustained record in a defined area.
Before you submit primary research: readiness checklist
If you have a primary drug discovery or pharmacology research paper and are deciding where to submit, use these questions:
- Is the central finding mechanistically validated in a human-relevant system or clinical context?
- Does the paper explain the therapeutic relevance of the finding, not just the basic science?
- Is the methodology described in sufficient detail for independent replication of key pharmacological assays?
- Does the paper address selectivity and off-target effects for any chemical tool or candidate compound?
- Would the finding interest drug discovery researchers outside your specific target or disease area?
- Are the pharmacokinetic or ADMET properties characterized if the paper involves drug candidates?
A Nature Reviews Drug Discovery manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.
Readiness check
Run the scan to check your manuscript against this list.
See your readiness score, top issues, and journal-fit signals in 1-2 minutes.
Alternative journal routing when Nature Reviews Drug Discovery is not the fit
If your manuscript looks like this | Better-fit route | Why |
|---|---|---|
Chemical biology mechanism with therapeutic relevance | Nature Chemical Biology or Cell Chemical Biology | Primary research format and mechanistic review culture fit better |
Medicinal chemistry series, SAR, or lead optimization | Journal of Medicinal Chemistry | Reviewers expect compound design, selectivity, and pharmacology detail |
Translational biotechnology platform with clinical path | Nature Biotechnology | Primary research and translational technology route |
Applied drug discovery and development review or commentary | Drug Discovery Today | More open route for applied synthesis and shorter opinion pieces |
Broad clinical or therapeutic impact with human relevance | Nature Medicine or specialist clinical journal | Primary translational evidence belongs outside NRDD |
Reviewer risk patterns for Nature Reviews Drug Discovery routing
Across drug discovery manuscripts targeting Nature Reviews Drug Discovery or being rerouted from it, the most useful first decision is often negative: this is not a primary research destination. Manusights internal analysis treats this as a failure pattern for Nature Reviews Drug Discovery readiness, and we observe it across abstracts, methods, original figures, pharmacology tables, references, cover letters, and proposed review outlines. In practice, editors consistently flag the mismatch between primary research evidence and commissioned review architecture. The three patterns below are the routing checks we would run before submission.
Primary research disguised as a review proposal
For manuscripts targeting Nature Reviews Drug Discovery, the first failure pattern is a package that says "review" but still reads like a primary paper. The abstract centers the authors' own compound series, the figures are original experimental results, the methods section describes assays, and the references are arranged to support a single study rather than a field synthesis. That package is not ready for Nature Reviews Drug Discovery, even if the science is strong.
The fix is a routing decision. If the paper has original target biology, medicinal chemistry, pharmacology, ADMET, screening, or animal-efficacy data, rebuild the cover letter, abstract, methods, figures, references, and supplementary files for Nature Chemical Biology, Journal of Medicinal Chemistry, Cell Chemical Biology, Nature Biotechnology, or a specialist pharmacology journal. If the goal is truly a Nature Reviews Drug Discovery proposal, remove the primary data posture and prepare a topic outline, reference map, display-item plan, author-qualification statement, and reason the synthesis is needed now.
Expert-author claim without synthesis architecture
For Nature Reviews Drug Discovery proposals, the second failure pattern is an author team with real expertise but no article architecture. The cover letter names a broad topic, the references are current, and the authors have strong papers, but the proposal does not explain what decision the review helps readers make. Nature Reviews Drug Discovery readers want structured interpretation: target-class maturity, modality tradeoffs, clinical translation bottlenecks, assay limitations, biomarker readiness, regulatory friction, and where the field is overclaiming.
The readiness package should therefore include a proposed table of contents, two to four display ideas, a reference map, and a thesis that is sharper than "recent advances." A review on targeted protein degradation, RNA therapeutics, antibody-drug conjugates, KRAS inhibitors, or AI in drug discovery cannot be a literature tour. It needs to tell readers what has matured, what remains fragile, and where claims in the field exceed evidence.
Without that architecture, Drug Discovery Today, Trends in Pharmacological Sciences, or a shorter perspective venue may be a better first route.
Primary research rerouted to the wrong comparison journal
Across Manusights submission reviews for drug discovery manuscripts initially pointed at Nature Reviews Drug Discovery, the third failure pattern is poor fallback routing. A medicinal chemistry manuscript goes to Nature Chemical Biology even though the real contribution is SAR. A target-validation paper goes to Journal of Medicinal Chemistry even though the compound is only a tool. A pharmacology paper goes to Cell Chemical Biology without selectivity profiling, pharmacokinetic exposure data, or a mechanistic figure that can survive specialist review.
The better readiness check starts with manuscript components. If the methods and figures revolve around compounds, selectivity, potency, and structure-activity relationships, Journal of Medicinal Chemistry is probably the cleanest route. If the figures explain biological mechanism through chemical tools, Nature Chemical Biology or Cell Chemical Biology may fit. If the story is platform translation, target validation, or clinical development pathway, Nature Biotechnology or Nature Medicine may be plausible only with much stronger translational evidence.
Nature Reviews Drug Discovery is the review destination that may cite these papers later, not the place to submit them now.
Frequently asked questions
No. Nature Reviews Drug Discovery publishes commissioned review and perspective-style content, not unsolicited primary research manuscripts. For primary drug discovery research, the correct targets are Nature Chemical Biology, Journal of Medicinal Chemistry, Nature Biotechnology, Cell Chemical Biology, or Drug Discovery Today depending on scope.
Nature Reviews Drug Discovery editors identify candidates based on sustained publication record, citation visibility, translational experience, and authority in a specific drug discovery area. Editors initiate most invitations, although authors can approach the editorial office with a concise proposal.
According to the 2024 JCR, Nature Reviews Drug Discovery has an impact factor of approximately 72.0. The high IF reflects the citation density of commissioned review articles rather than an open submission path for ordinary research papers.
For primary drug discovery research with mechanistic depth, Nature Chemical Biology and Cell Chemical Biology are strong targets. For medicinal chemistry and structure-activity relationships, Journal of Medicinal Chemistry is the field's flagship. For broader translational biotechnology, Nature Biotechnology or Nature Medicine may be appropriate.
Prepare a concise topic rationale, author-qualification statement, article-type fit, recent reference map, and explanation of why the synthesis is needed now. The proposal should not read like a primary research submission.
Sources
- 1. Nature Reviews Drug Discovery author information, Nature Portfolio.
- 2. Nature Chemical Biology author information, Nature Portfolio.
- 3. Journal of Medicinal Chemistry author guidelines, American Chemical Society.
- 4. Cell Chemical Biology author information, Cell Press.
- 5. Clarivate Journal Citation Reports 2024, Clarivate.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.